4. Experiencing active UC (flare) despite a therapeutic dose of an oral 5-ASA (e.g., mesalamine ≥ 2.4 g/day for ≥ 6 weeks prior to randomization, or equivalent). At screening, photographic evidence of active UC based on mucosal appearance must be obtained.